Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04922528
Other study ID # H21-01375
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2021
Est. completion date January 2023

Study information

Verified date June 2021
Source University of British Columbia
Contact Karan J D'Souza, MD MPH MM
Phone 6048755094
Email karan.dsouza@alumni.ubc.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective randomized controlled trial evaluating the use of a fluorescent dye, indocyanine green (ICG), in the identification of important bile duct anatomy during emergent same-admission cholecystectomy. Participants will be randomized into either the control arm, which uses the standard of care white light during laparoscopy or the intervention arm, which will use ICG fluorescent cholangiography as an adjunct to white light to visualize the biliary anatomy. The investigators hypothesize that the use of fluorescent cholangiography will increase the rates of identification of important biliary anatomy during laparoscopic cholecystectomy. The effectiveness, feasibility, and safety will be compared between the two groups using a post-operative survey form the surgeons will complete prior to exiting the operating room.


Description:

Near-infrared fluorescent imaging techniques have shown promise in aiding to delineate and visualize extrahepatic biliary structures. Indocyanine green (ICG) is a water-soluble fluorescent dye that has been shown to improve visualization of biliary anatomy under fluorescent cholangiography. The standard of care for many acute biliary disease conditions, such as acute cholecystitis, remains early laparoscopic cholecystectomy. Even though real-time fluorescent cholangiography using ICG has the potential to enhance the visualization of biliary structures and anatomy, and therefore reduce the risk for bile duct injury, the majority of the studies published to date exclude acute biliary disease patients. The pathophysiology of acute biliary disease processes is associated with inflammation and adhesions that increase the challenge of achieving a critical view of safety. The investigators propose that using ICG and fluorescent cholangiography near-infrared imaging techniques as an adjunct in acute care laparoscopic cholecystectomies has the potential to help mitigate the increased risk of bile duct injury by increasing extrahepatic biliary structure detection and surgeon confidence. Eligible patients will be identified through their initial clinical evaluation, which will be verified by the patient's primary surgeon. If and once a patient has been confirmed as eligible, the surgeon or designate will introduce the clinical trial design in detail. If after being introduced to the study and having had the opportunity to ask questions, the patient is willing to participate, the patient will be asked to review and sign the informed consent document. Upon entry into the clinical trial, the allocation sequence will be generated using a block randomization schema with computer-generated random numbers in a 1:1 ratio, with block sizes of 4 by a co-investigator with no clinical involvement in the trial. The same co-investigator will prepare sequentially numbered, opaque, sealed and stapled envelopes and stored them in a locked cabinet in the operating room control desk. Each envelope contained instructions for the arm the participant had been randomly assigned to, either treatment (ICG cholangiography) or control (standard white light only) arms. After the research team member has obtained the participant's consent, the surgeon or designates will obtain the next consecutively numbered envelope and proceed to open it after the patient is anesthetized and prior to beginning the surgery. The patient will be blinded to the result of the randomization until after surgery as the envelope will be opened only after the patient has received their general anesthetic. No blinding of the surgical team, research team members or outcomes assessors will be used in this study given the procedural nature and acute condition of the patients included.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 340
Est. completion date January 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Admission or consultation by the Acute Care Surgery (ACS) service - Diagnosis of acute biliary disease requiring index laparoscopic cholecystectomy - Diagnoses of acute cholangitis, choledocholithiasis, and gall stone pancreatitis may be included. However, they must have cleared ducts confirmed via endoscopic ultrasound, ultrasound, ERCP, and/or laboratory investigations. - Ability to understand and follow study procedures and protocols, and provide signed informed consent. Exclusion Criteria: - Female patients who are pregnant or currently breastfeeding - Known pre-existing liver disease, including cirrhosis - Known allergy to iodine or shellfish - Known allergy to indocyanine green (ICG)

Study Design


Intervention

Procedure:
Laparoscopic Cholecystectomy with Fluorescent Cholangiography
Indocyanine green is a fluorophore molecule which is metabolized by the liver and excreted exclusively through the biliary system. Intra-operatively, near-infared imaging via the laparoscope will be used to visualize the biliary anatomy in the intervention arm, as an adjunct to standard of care white-light imaging.
Laparoscopic Cholecystectomy with White Light Imaging
As per the current standard of care, patients undergoing laparoscopic cholecystectomies will have it completed using white light imaging through the laparoscope.

Locations

Country Name City State
Canada Vancouver General Hospital Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Bleszynski MS, DeGirolamo KM, Meneghetti AT, Chiu CJ, Panton ON. Fluorescent Cholangiography in Laparoscopic Cholecystectomy: An Updated Canadian Experience. Surg Innov. 2020 Feb;27(1):38-43. doi: 10.1177/1553350619885792. Epub 2019 Nov 19. — View Citation

Zroback C, Chow G, Meneghetti A, Warnock G, Meloche M, Chiu CJ, Panton ON. Fluorescent cholangiography in laparoscopic cholecystectomy: the initial Canadian experience. Am J Surg. 2016 May;211(5):933-7. doi: 10.1016/j.amjsurg.2016.01.013. Epub 2016 Feb 23. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events Any adverse events associated with the administration or use of ICG fluorescent cholangiography Through participant discharge, an average of 1 week
Other Procedural complications Any complications associated with the cholecystectomy Through participant discharge, an average of 1 week
Primary Detection rate of extrahepatic biliary structures The extrahepatic biliary structures which we will be assessing the identification of include: Cystic Duct (CD), Right Hepatic Duct (RHD), Common Hepatic Duct (CHD), Common Bile Duct (CBD), Cystic Duct - Gall Bladder junction (CD-GB), and Cystic Duct - Common Bile Duct junction (CD-CBD). Intraoperatively
Secondary Operative success Rates of laparoscopic subtotal cholecystectomy and laparoscopic cholecystostomy tube placement. Intraoperatively
Secondary Rates of conversion Rate of conversion to open cholecystectomy. Intraoperatively
Secondary Operative time From the time of opening the skin to the time of closure. Intraoperatively
Secondary Surgeon satisfaction Operating surgeons satisfaction (as rated by post-procedural survey) with the utility and feasibility of the modality. Through participant discharge, an average of 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT03536247 - Papillary Balloon Dilation Versus Intraductal Lithotripsy N/A
Recruiting NCT05035433 - Effect of the Sequence of Dilatation and Lithotripsy on the Treatment of Choledocholithiasis With ERCP N/A
Not yet recruiting NCT06060002 - Role of Prophylactic Biliary Stent in Reducing the Recurrence of Choledocholithiasis N/A
Recruiting NCT06041113 - Recurrent Extrahepatic Bile Duct Stones as a Late Complication of ERCP in Patients With Coexisting Intra- and Extrahepatic Bile Duct Stones
Completed NCT02461147 - Prospective Validation of "Cholecystectomy First" Strategy for Gallstone Migration
Recruiting NCT00416234 - Laparoendoscopic Rendez Vous Versus Standard Two Stage Approach for the Management of Cholelithiasis/Choledocholithiasis N/A
Active, not recruiting NCT05592795 - Explore the Effects and Mechanisms of ERCP and EST on Biliary Microecology
Recruiting NCT05056506 - EPLBD With Limited EST vs. EPLBD for Choledocholithiasis N/A
Completed NCT02515474 - Comparison of LCBDE vs ERCP + LC for Choledocholithiasis N/A
Recruiting NCT05429203 - Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope N/A
Completed NCT01824186 - Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy N/A
Completed NCT02647593 - The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis
Not yet recruiting NCT06066372 - Application of Machine Learning Models to Reduce Need for Diagnostic EUS or MRCP in Patients With Intermediate Likelihood of Choledocholithiasis
Completed NCT04716166 - Incentive Spirometry and Upper Abdominal Laparoscopic Surgery N/A
Completed NCT03074201 - Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP N/A
Withdrawn NCT01475864 - Prospective Evaluation of the Covered Self-expandable Metal Stents (CSEMS) for Incomplete Biliary Stone Clearance N/A
Recruiting NCT06265311 - IDUS in CBD Stone Recurrence High Risk Patients N/A
Completed NCT02870686 - EUS Guided ERCP in Bile Duct Stone Removal N/A
Recruiting NCT05611840 - RCT on Robotic vs. Endo-laparoscopic Approach for Difficult Choledocholithiasis N/A
Recruiting NCT03102281 - Microbiomes in Patients of Recurrent Common Bile Duct Stones N/A